etamzilat solutie injectabila 12,5 %
gntls srl, uzina experimentala - etamsylatum - solutie injectabila - 12,5 %
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
afinitor comprimate 2,5 mg
novartis pharma ag - everolimus - comprimate - 2,5 mg
impaza comprimate de supt
fsp materia medica holding srl - o combinatie - comprimate de supt
aminazin solutie injectabila 25 mg/ml
zdorovie narodu srl, if din harkov - chlorpromazinum - solutie injectabila - 25 mg/ml
ramilong comprimate 10 mg
lekpharm srl - ramiprilum - comprimate - 10 mg
ramilong comprimate 5 mg
lekpharm srl - ramiprilum - comprimate - 5 mg
vitrum superstress comprimate filmate
unipharm inc. - combinatie - comprimate filmate
kisplyx
eisai gmbh - lenvatinib mesilate - carcinomul, celula renală - agenți antineoplazici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.